Work

The Role of Minocycline in Alzheimer’s Disease: Acetylcholinesterase Inhibition and Neuroprotective Mechanisms

Year: 2025

Type: article

Abstract: Minocycline, a semisynthetic tetracycline antibiotic, has garnered attention for its potential therapeutic effects on Alzheimer’s disease (AD). It has been extensively studied for its potential neuroprotective effects beyond its antimicrobial properties. This review explores the pharmacological mechanisms, therapeutic applications, and clinical trials of minocycline, with a particular focus on its role in neurodegenerative diseases such as AD. Acetylcholinesterase (AChE) is the enzyme responsible for the breakdown of acetylcholine in the synaptic cleft, and its inhibition is a key therapeutic target in AD treatment. By inhibiting AChE, minocycline increases acetylcholine levels in the brain, which may improve cognitive function and mitigate neurodegenerative processes. The study concluded that minocycline is a promising therapeutic agent for the treatment of AD. As this condition is affecting more people worldwide, minocycline could lead to effective and timely treatment for people suffering from this disease.

Source: Asian Journal of Research in Medical and Pharmaceutical Sciences

DOI: 10.9734/ajrimps/2025/v14i1298

Authors: Faith Omosigho, Matthew Babalola, Fatimoh Ikeoluwa Egbinola, Ogbonna Kosisochukwu Doris, Kernen Paul Agwaza, Ewaoluwa Promise Owoyemi, Sushma Bhuvanagiri, James Michael Ugochukwu

Institutions: Delta State University, University of Abuja, Obafemi Awolowo University, Nasarawa State University, University of Jos, Federal University of Technology, University of the West of Scotland, Michael Okpara University of Agriculture

Language: English

Topic: Cholinesterase and Neurodegenerative Diseases

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4408071101

FWCI:

Cites:

Cited by:

Related to: 10